Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
9
×
clinical trials
biotech
boston
san francisco blog main
amgen
deals
new york blog main
roche
san francisco top stories
alnylam pharmaceuticals
fda
inclisiran
new york
new york top stories
regeneron pharmaceuticals
sanofi
avapritinib
blueprint medicines
cancer
cancer drugs
cholesterol
eli lilly
genentech
investing
medullary thyroid cancer
non-small cell lung cancer
novartis
pcsk9
pcsk9 inhibitors
pralsetinib
praluent
repatha
rna interference
selpercatinib
the medicines co.
What
drug
9
×
medicines
9
×
fda
cancer
cholesterol
genetic
ipo
medco
approval
blueprint
company
diseases
lowering
muscle
new
research
ret
roche
team
twice
aces
acquire
address
ago
agreed
analysis
announced
approves
big
billion
bio
biotech
biotechs
bring
bringing
brings
candidate
carries
cash
caught
Language
unset
9
×
Current search:
drug
×
unset
×
" national top stories "
×
medicines
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing